# Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.

> **NCT06528613** · — · RECRUITING · sponsor: **Elpen Pharmaceutical Co. Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06528613
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528613, "Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06528613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*